Rare disease news, mapped to the diseases behind the headlines. AI-classified across pipeline, policy, funding, science, and community.
Be among the first to receive Kisho Intelligence Briefings
Showing news related to
Showing 1–2 of 2 stories
Recent research identifies TRIB1AL as a potential target for steatotic liver disease through integrative genetic and liver transcriptomic analyses. This discovery could pave the way for new therapeutic strategies in managing this condition.
A new study integrates body composition analysis with machine learning to non-invasively identify metabolic dysfunction-associated fatty liver disease (MAFLD). This large-scale health examination highlights innovative approaches to diagnosing a condition affecting millions.
Get the week's most important rare disease developments — pipeline moves, policy changes, and funding signals — delivered to your inbox every Monday.
Free weekly briefing. Unsubscribe anytime.